The whole-body ischemia-reperfusion response that occurs during cardiac arrest and subsequent restoration of systemic circulation results in a series of pathophysiological processes that have been termed as PCAS.

2. Post Cardiac Arrest Syndrome (PCAS)
DelveInsight © 2019 | All rights reservedDelveInsight © 2019 | All rights reserved
01
02
03
The whole-body ischemia-reperfusion response that occurs
during cardiac arrest and subsequent restoration of systemic
circulation results in a series of pathophysiological
processes that have been termed as PCAS.
04
PCAS components comprise post-cardiac arrest brain
injury, post-cardiac arrest myocardial dysfunction, the
systemic ischemia-reperfusion response and persistent
precipitating pathology.
An In-Hospital Cardiac Arrest means access is available to
medical practitioners in advanced resuscitation techniques,
whereas an Out-of-Hospital Cardiac Arrest entails a
significant response time for emergency services.
The post cardiac arrest period is segmented into four
phases includes, immediate post-arrest phase, early
post-arrest phase, intermediate phase and recovery
phase.

3. DelveInsight © 2019 | All rights reserved
PCAS Epidemiology
There were
1,150,165
diagnosed
incident cases
of sudden
cardiac arrest
(SCA) in 2016
in 7 major
markets.
More
than 350,000
people are
affected each
year with out
of hospital
cardiac arrest
in the US.
Incident cases
of IHSCA* and
OHSCA* in
Japan was
found to be
72,117 and
123,000 in
2016.
Germany had
the highest
diagnosed
incident cases
of Sudden
Cardiac Arrest
with 148,438
cases among
Europe.
Approx 2/3 of
PCAS
associated
mortality are
due to brain
injury and
contributes
to life time
disability.
* IHSCA (In Hospital Sudden Cardiac Arrest) and OHSCA (Out of
Hospital Sudden Cardiac Arrest)

4. DelveInsight © 2019 | All rights reserved
PCAS Market Outlook
DelveInsight © 2019 | All rights reserved
The United States accounts for the
largest Post-Cardiac Arrest Syndrome
market size in comparison to EU5
(the United Kingdom, Germany, Italy,
France, and Spain) and Japan.
At present, there is no therapy approved
for PCAS treatment/prevention and the
current standard of neuroprotection is
targeted temperature management and
controlled Oxygenation. The current
treatment approach has shown good
results in many cases but still unable to
reduce the mortality incidences.
PCAS Market analysis carried out for
the period of 2016-2027
demonstrates that PCAS Market size
was found out to be USD 547.0
Million in 2016 in seven major
markets*.
Although targeted temperature
management has been proven
to be very effective and used in
PCAS patients, the related
adverse events hampers the
quality of life of the patients.
*7 Major Markets- United States, EU-5 (Germany, Italy, Spain,
France, Germany), Japan

5. DelveInsight © 2019 | All rights reserved
PCAS Emerging Drug and Companies
Drug- Xenon
Company- NeuroproteXeon/ Mallinckrodt
The Food and Drug Administration has
granted Fast Track designation to xenon gas
for inhalation for use in post-cardiac arrest
patients. Xenon gas therapy is by
NeuroproteXeon/Mallinckrodt. The company
is exploring the benefits of Xenon gas as an
add-on therapy with current standard
therapy Oxygenation and Targeted
temperature management.

6. Complete Information
DelveInsight © 2019 | All rights reserved
For complete information on
Post-Cardiac Arrest Syndrome Market Insights, Epidemiology & Market Forecast-2028
please click the link below
CLICK HERE
OR
Write Us At
info@delveinsight.com

7. About Delveinsight
DelveInsight © 2019 | All rights reserved
About
DelveInsight is a premier Business Consulting
and Market Research firm focused exclusively on
the life science segment. With a wide array of
smart end-to-end solutions, the firm helps the
global Pharmaceutical and Bio-Tech companies
formulate prudent business decisions for
improving their performances to stay ahead of
the competitors.
Mission
To provide “insights across the value chain” and
helping the organization to take a prudent
business decision through the use and analysis of
actionable market intelligence. The mission also
is to provide the most effective result and
efficient service with utmost client care for
maintaining a long-term relationship with them.
Vision
To be the most trusted market research & business
consulting firm in the world; and to continue
enable the Pharma & Bio-Tech companies to
achieve their goals with the best strategic insight
and competitive solution. The vision also is
inclusive of becoming a one-stop solution
provider for the entire gamut of drug development
process.
1 2 3

8. Services by delveinsight
DelveInsight © 2019 | All rights reserved
OpportunityAssessment
Pipeline
Consulting
MarketIntelligence
Forecasting
ReportStore
Competitive Analysis
PharmDelve

9. Contact us
info@delveinsight.com
+91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight
DelveInsight © 2019 | All rights reserved